Approximately 15 HPV types cause virtually all cervical cancers;however, the current HPV vaccines cover only 2 HPV types causing ~70% of invasive cervical cancer and have no therapeutic effect on established infections that place women at risk. Thus, all women will need some kind of routine cervical screening for the foreseeable future. Importantly, the majority of women alive today have not been vaccinated and therefore are at risk for cervical cancer. The US Preventive Services Task Force recommendations on cervical cancer screening have not been updated for nearly a decade and performance measures for cervical cancer screening focus on population coverage rather than on follow-up among women with positive screening and diagnostic tests. Toward improving US cervical cancer prevention, we propose multi-tiered assessments at the statewide, systems, provider and patient levels including targeted medical record review of failures in the screening process;geospatial mapping of population-based screening, diagnosis and treatment;and application of community-based participatory approaches (CBPR) in clinical settings to identify barriers and facilitators across the processes of care including those that may enable novel patient-centered screening options. The cornerstone of our coordinated, multidisciplinary program is the New Mexico HPV Pap Registry which transcends limitations of organizational monitoring by mandating statewide surveillance of all cervical cancer screening, diagnosis and treatment. New Mexico is home to a high proportion of ethnically diverse (i.e., American Indian and Hispanic), rural, impoverished, medically disenfranchised and health-disparate populations at high-risk for cervical cancer.
The specific aims of this application are to 1) Establish the New Mexico HPV Outcomes, Practice Effectiveness and Surveillance (NM-HOPES) PROSPR Research Center;2) Establish a sustainable Screening Process Documentation Unit providing data on patients during their course of cervical cancer screening care;and 3) Integrate and fund 3 research projects with the overarching aim of informing practice and targeted interventions supported by comparative effectiveness evaluations of real-world cervical cancer screening practice and outcomes versus guidelines and innovations.

Public Health Relevance

Toward improving cervical prevention efforts among rural, impoverished, medically disenfranchised and health-disparate populations of the Southwestern US, we propose a multidisciplinary research center focusing on barriers and facilitators of systems and primary care practice, cost- and comparative effectiveness evaluations and participatory research approaches to enable patient-centered solutions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA164336-03
Application #
8531007
Study Section
Special Emphasis Panel (ZCA1-SRLB-R (O1))
Program Officer
Ambs, Anita
Project Start
2011-09-23
Project End
2016-05-31
Budget Start
2013-08-30
Budget End
2014-05-31
Support Year
3
Fiscal Year
2013
Total Cost
$785,173
Indirect Cost
$245,072
Name
University of New Mexico Health Sciences Center
Department
Pathology
Type
Schools of Medicine
DUNS #
829868723
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Rutter, Carolyn M; Kim, Jane J; Meester, Reinier G S et al. (2017) Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev :
McDonald, Yolanda J; Schwind, Michael; Goldberg, Daniel W et al. (2017) An analysis of the process and results of manual geocode correction. Geospat Health 12:526
Cuzick, Jack; Myers, Orrin; Lee, Ji-Hyun et al. (2017) Outcomes in Women With Cytology Showing Atypical Squamous Cells of Undetermined Significance With vs Without Human Papillomavirus Testing. JAMA Oncol 3:1327-1334
McCarthy, Anne Marie; Kim, Jane J; Beaber, Elisabeth F et al. (2016) Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity. Am J Prev Med 51:507-12
Haas, Jennifer S; Sprague, Brian L; Klabunde, Carrie N et al. (2016) Provider Attitudes and Screening Practices Following Changes in Breast and Cervical Cancer Screening Guidelines. J Gen Intern Med 31:52-9
Armstrong, Katrina; Kim, Jane J; Halm, Ethan A et al. (2016) Using lessons from breast, cervical, and colorectal cancer screening to inform the development of lung cancer screening programs. Cancer 122:1338-42
Corley, Douglas A; Haas, Jennifer S; Kobrin, Sarah (2016) Reducing Variation in the ""Standard of Care"" for Cancer Screening: Recommendations From the PROSPR Consortium. JAMA 315:2067-8
Gage, Julia C; Hunt, William C; Schiffman, Mark et al. (2016) Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program. Cancer Epidemiol Biomarkers Prev 25:36-42
Gage, Julia C; Hunt, William C; Schiffman, Mark et al. (2016) Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines. Obstet Gynecol 128:1248-1257
Tosteson, Anna N A; Beaber, Elisabeth F; Tiro, Jasmin et al. (2016) Variation in Screening Abnormality Rates and Follow-Up of Breast, Cervical and Colorectal Cancer Screening within the PROSPR Consortium. J Gen Intern Med 31:372-9

Showing the most recent 10 out of 28 publications